Glycogene

Founded in 2019 and based in Wuhan, China, Glycogene began operations with a focus on nucleic acid and carbohydrate raw materials. The company expanded its activities through its subsidiary Wuhan Tangzhi Pharmaceutical Co. , Ltd. , developing mRNA and oligonucleotide synthesis products.

It serves both domestic and international markets, including North America and Europe. Its founder and management team have not been publicly disclosed. In August 2025, the company completed a venture funding round with investment from Huaxin Capital to support product development and international expansion. The company manufactures high-purity nucleic acid and carbohydrate raw materials.

Its portfolio includes mRNA synthesis raw materials, oligonucleotide synthesis raw materials, and other biochemical synthesis inputs for drug research, development, and diagnostics. Glycogene’s customer base includes pharmaceutical firms and biotechnology companies across multiple global regions. The company generates revenue through a B2B model, supplying custom and bulk raw materials to pharmaceutical and biotechnology clients. Long-term supply contracts and tailored product offerings contribute to recurring revenue streams, particularly for mRNA and oligonucleotide synthesis materials.

Following its August 2025 venture funding, Glycogene plans to expand its product line with additional mRNA and oligonucleotide materials by mid-2026. The company is also preparing to establish a broader market presence in North America and Europe by 2027.